Ionis Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Ionis Pharmaceuticals, Inc. (IONS) reported Net Income (Loss) Available to Common Stockholders, Basic of $123.55 million for the 6-month period ending 2025-12-31, per its 10-Q filed 2025-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was $123.55M.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was $224.61M.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$356.01M, a 293.70% decline year-over-year.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$24.57M, a 193.93% decline year-over-year.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$444.46M, a 258.42% decline from fiscal 2019.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was $280.56M, a 1.33% increase from fiscal 2018.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was $276.87M, a 1373.33% increase from fiscal 2017.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2017 was $18.79M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $123.55M 10-Q · filed 2025-07-30 | |||||||
| 2025-06-30 | $123.55M 10-Q · filed 2026-07-29 | |||||||
| 2021-12-31 | $224.61M 10-K · filed 2023-02-22 | |||||||
| 2020-12-31 | -$356.01M 10-K · filed 2022-02-25 | -$340.27M 10-K · filed 2021-02-24 | -$380.58M derived: sum of 2 quarters · filed 2022-02-25 | -$406.23M derived: sum of 3 quarters · filed 2022-02-25 | -$444.46M 10-K · filed 2023-02-22 | -$451.49M 10-K · filed 2021-02-24 | ||
| 2020-09-30 | -$24.57M 10-Q · filed 2021-11-03 | -$31.05M 10-Q · filed 2020-11-04 | -$50.22M derived: sum of 2 quarters · filed 2021-11-03 | -$89.94M 10-Q · filed 2021-11-03 | -$111.22M 10-Q · filed 2020-11-04 | $93.87M derived: sum of 4 quarters · filed 2021-11-03 | ||
| 2020-06-30 | -$25.65M 10-Q · filed 2021-08-04 | -$31.86M 10-Q · filed 2020-08-05 | -$65.36M 10-Q · filed 2021-08-04 | -$80.17M 10-Q · filed 2020-08-05 | $118.44M derived: sum of 3 quarters · filed 2021-08-04 | $144.60M derived: sum of 4 quarters · filed 2021-08-04 | ||
| 2020-03-31 | -$39.71M 10-Q · filed 2021-05-05 | -$48.30M 10-Q · filed 2020-05-06 | $144.09M derived: sum of 2 quarters · filed 2021-05-05 | $170.25M derived: sum of 3 quarters · filed 2021-05-05 | $169.31M derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | $183.79M 10-K · filed 2021-02-24 | $209.95M derived: sum of 2 quarters · filed 2021-02-24 | $209.02M derived: sum of 3 quarters · filed 2021-02-24 | $280.56M 10-K · filed 2022-02-25 | $296.56M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $26.16M 10-Q · filed 2020-11-04 | $25.23M derived: sum of 2 quarters · filed 2020-11-04 | $112.76M 10-Q · filed 2020-11-04 | $432.46M derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | -$933.00K 10-Q · filed 2020-08-05 | $86.63M 10-Q · filed 2020-08-05 | $406.30M derived: sum of 3 quarters · filed 2020-08-05 | $401.74M derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $87.54M 10-Q · filed 2020-05-06 | $407.24M derived: sum of 2 quarters · filed 2020-05-06 | $402.67M derived: sum of 3 quarters · filed 2020-05-06 | $364.74M derived: sum of 4 quarters · filed 2020-05-06 | ||||
| 2018-12-31 | $319.69M 10-K · filed 2020-03-02 | $315.13M derived: sum of 2 quarters · filed 2020-03-02 | $277.20M derived: sum of 3 quarters · filed 2020-03-02 | $276.87M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | -$4.56M 10-K · filed 2020-03-02 | -$4.62M 10-Q · filed 2018-11-06 | -$42.49M derived: sum of 2 quarters · filed 2020-03-02 | -$43.16M 10-Q · filed 2019-11-06 | -$43.16M 10-Q · filed 2018-11-06 | -$46.83M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | -$37.93M 10-K · filed 2020-03-02 | -$38.53M 10-Q · filed 2019-08-08 | -$42.27M derived: sum of 3 quarters · filed 2020-03-02 | -$44.24M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | -$1.21M 10-K · filed 2020-03-02 | -$4.34M derived: sum of 2 quarters · filed 2020-03-02 | -$6.31M derived: sum of 3 quarters · filed 2020-03-02 | -$9.40M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | -$3.12M 10-K · filed 2019-03-01 | $2.72M 10-K · filed 2018-02-28 | -$5.10M derived: sum of 2 quarters · filed 2019-03-01 | -$8.19M derived: sum of 3 quarters · filed 2019-03-01 | $18.79M 10-K · filed 2020-03-02 | $9.66M 10-K · filed 2018-02-28 | ||
| 2017-09-30 | -$1.98M 10-K · filed 2019-03-01 | -$419.00K 10-Q · filed 2017-11-07 | -$5.06M derived: sum of 2 quarters · filed 2019-03-01 | $16.32M 10-Q · filed 2018-11-06 | $2.89M 10-Q · filed 2017-11-07 | $29.77M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-06-30 | -$3.09M derived: 10-Q 6 month − 10-K 3 month · filed 2018-08-07 | $5.88M 10-Q · filed 2018-08-07 | $31.74M derived: sum of 3 quarters · filed 2019-03-01 | $39.09M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $8.96M 10-K · filed 2019-03-01 | $3.47M 10-Q · filed 2017-05-09 | $34.83M derived: sum of 2 quarters · filed 2019-03-01 | $42.18M derived: sum of 3 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $25.86M 10-K · filed 2018-02-28 | $33.22M derived: sum of 2 quarters · filed 2018-02-28 | ||||||
| 2016-09-30 | $7.35M 10-K · filed 2018-02-28 | |||||||
| 2015-06-30 | $35.65M 10-K · filed 2017-03-01 | $18.93M 10-Q · filed 2016-08-09 | $49.98M derived: sum of 3 quarters · filed 2017-03-01 | $23.31M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | -$16.72M 10-Q · filed 2015-05-05 | $14.34M derived: sum of 2 quarters · filed 2016-02-26 | -$12.34M derived: sum of 3 quarters · filed 2016-02-26 | -$24.42M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-12-31 | $31.05M 10-K · filed 2016-02-26 | $4.38M derived: sum of 2 quarters · filed 2016-02-26 | -$7.70M derived: sum of 3 quarters · filed 2016-02-26 | -$38.98M 10-K · filed 2015-03-02 | ||||
| 2014-09-30 | -$26.68M 10-K · filed 2015-03-02 | -$38.76M derived: sum of 2 quarters · filed 2015-03-02 | -$70.04M 10-Q · filed 2014-11-07 | -$94.31M derived: sum of 4 quarters · filed 2015-05-05 | ||||
| 2014-06-30 | -$12.08M 10-K · filed 2015-03-02 | -$43.36M 10-Q · filed 2014-08-04 | -$67.64M derived: sum of 3 quarters · filed 2015-05-05 | -$92.21M derived: sum of 4 quarters · filed 2015-05-05 | ||||
| 2014-03-31 | -$31.28M 10-Q · filed 2015-05-05 | -$55.56M derived: sum of 2 quarters · filed 2015-05-05 | -$80.13M derived: sum of 3 quarters · filed 2015-05-05 | -$90.25M derived: sum of 4 quarters · filed 2015-05-05 | ||||
| 2013-12-31 | -$24.28M 10-K · filed 2015-03-02 | -$48.85M derived: sum of 2 quarters · filed 2015-03-02 | -$58.97M derived: sum of 3 quarters · filed 2015-03-02 | -$60.64M 10-K · filed 2015-03-02 | ||||
| 2013-09-30 | -$24.57M 10-K · filed 2015-03-02 | -$34.70M derived: sum of 2 quarters · filed 2015-03-02 | -$36.37M 10-Q · filed 2014-11-07 | -$39.01M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-06-30 | -$10.13M 10-K · filed 2015-03-02 | -$11.80M 10-Q · filed 2014-08-04 | -$14.44M derived: sum of 3 quarters · filed 2015-03-02 | -$52.07M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-03-31 | -$1.67M 10-K · filed 2015-03-02 | -$4.31M derived: sum of 2 quarters · filed 2015-03-02 | -$41.95M derived: sum of 3 quarters · filed 2015-03-02 | -$43.16M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | -$2.64M 10-K · filed 2014-03-03 | -$40.28M derived: sum of 2 quarters · filed 2014-03-03 | -$41.48M derived: sum of 3 quarters · filed 2014-03-03 | -$65.48M 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | -$37.64M 10-K · filed 2014-03-03 | -$38.85M derived: sum of 2 quarters · filed 2014-03-03 | -$62.84M 10-Q · filed 2013-11-05 | -$82.88M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-06-30 | -$1.21M 10-K · filed 2014-03-03 | -$25.20M 10-Q · filed 2013-08-06 | -$45.24M derived: sum of 3 quarters · filed 2014-03-03 | -$72.12M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-03-31 | -$24.00M 10-K · filed 2014-03-03 | -$44.03M derived: sum of 2 quarters · filed 2014-03-03 | -$70.91M derived: sum of 3 quarters · filed 2014-03-03 | -$88.80M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2011-12-31 | -$20.04M 10-K · filed 2013-02-28 | -$46.92M derived: sum of 2 quarters · filed 2013-02-28 | -$64.81M derived: sum of 3 quarters · filed 2013-02-28 | -$84.80M 10-K · filed 2014-03-03 | ||||
| 2011-09-30 | -$26.88M 10-K · filed 2013-02-28 | -$44.77M derived: sum of 2 quarters · filed 2013-02-28 | -$64.77M 10-Q · filed 2012-11-06 | -$78.75M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | -$17.89M 10-K · filed 2013-02-28 | -$37.88M 10-Q · filed 2012-08-06 | -$51.87M derived: sum of 3 quarters · filed 2013-02-28 | -$64.32M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | -$19.99M 10-K · filed 2013-02-28 | -$33.98M derived: sum of 2 quarters · filed 2013-02-28 | -$46.43M derived: sum of 3 quarters · filed 2013-02-28 | -$71.59M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | -$13.98M 10-K · filed 2012-02-29 | -$26.44M derived: sum of 2 quarters · filed 2012-02-29 | -$51.59M derived: sum of 3 quarters · filed 2012-02-29 | -$61.25M 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | -$12.45M 10-K · filed 2012-02-29 | -$37.61M derived: sum of 2 quarters · filed 2012-02-29 | -$47.27M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | -$25.15M 10-K · filed 2012-02-29 | -$34.81M derived: sum of 2 quarters · filed 2012-02-29 | ||||||
| 2010-03-31 | -$9.66M 10-K · filed 2012-02-29 | |||||||
| 2009-12-31 | $155.07M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |